Life science-bolaget Bico \u00f6kade oms\u00e4ttningen och den organiska tillv\u00e4xten i andra kvartalet samtidigt som ebitda v\u00e4nde till positivt resultat.\n <\/p>\n
Oms\u00e4ttningen steg 3,7 procent till 336,1 miljoner kronor (324,2). Den organiska tillv\u00e4xten var 7,3 procent (-17,0).\n <\/p>\n
Justerat ebitda uppgick till 20,1 miljoner kronor (-49,7), med en justerad ebitda-marginal p\u00e5 6,0 procent. Ebitda blev 15,6 miljoner kronor (-52,5), motsvarande en ebitda-marginal p\u00e5 4,6 procent.\n <\/p>\n
Nettoresultatet fr\u00e5n kvarvarande verksamheter f\u00f6rb\u00e4ttrades till -37,2 miljoner kronor (-181,7). Resultatet per aktie efter utsp\u00e4dning fr\u00e5n kvarvarande verksamheter blev -0,53 kronor (-2,55).\n <\/p>\n
Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten uppgick till -53,0 miljoner kronor (-28,2).\n <\/p>\n
Avg\u00e5ende vd Maria Forss uppger att bolaget hade fortsatt bra momentum inom b\u00e4nkinstrument och f\u00f6rbrukningsvaror, medan den projektbaserade verksamheten fortsatt var utmanande. Initiativ inom kommersiell och operationell effektivitet bidrog enligt vd till den tydliga l\u00f6nsamhetsf\u00f6rb\u00e4ttringen.\n <\/p>\n
Under kvartalet lanserade Bico G.PURE, en l\u00f6sning f\u00f6r automatiserad rening av DNA, samt den AI-baserade applikationen Confluency AI.\n <\/p>\n
N\u00e5gon prognos l\u00e4mnas inte i rapporten.\n <\/p>\n
Nyckeltal, Mkr<\/p>\n<\/td>\n
Q2 2026<\/p>\n<\/td>\n
Q2 2025<\/p>\n<\/td>\n
F\u00f6r\u00e4ndring \u00e5r f\u00f6r \u00e5r<\/p>\n<\/td>\n<\/tr>\n
Oms\u00e4ttning<\/p>\n<\/td>\n
336,1<\/p>\n<\/td>\n
324,2<\/p>\n<\/td>\n
3,7%<\/p>\n<\/td>\n<\/tr>\n
Justerad Ebitda<\/p>\n<\/td>\n
20,1<\/p>\n<\/td>\n
-49,7<\/p>\n<\/td>\n
–<\/p>\n<\/td>\n<\/tr>\n
Ebitda<\/p>\n<\/td>\n
15,6<\/p>\n<\/td>\n
-52,5<\/p>\n<\/td>\n
–<\/p>\n<\/td>\n<\/tr>\n
Nettoresultat<\/p>\n<\/td>\n
-37,2<\/p>\n<\/td>\n
-181,7<\/p>\n<\/td>\n
–<\/p>\n<\/td>\n<\/tr>\n
Resultat per aktie, kronor<\/p>\n<\/td>\n
-0,53<\/p>\n<\/td>\n
-2,55<\/p>\n<\/td>\n
–<\/p>\n<\/td>\n<\/tr>\n
newsroom@finwire.se
\n
\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Life science-bolaget Bico \u00f6kade oms\u00e4ttningen och den organiska tillv\u00e4xten i andra kvartalet samtidigt som ebitda v\u00e4nde till positivt…\n","protected":false},"author":2,"featured_media":345146,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,34315,70,71,34,31,33,32,30],"class_list":["post-345145","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-cellink","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/117123385015952457","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/345145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=345145"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/345145\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/345146"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=345145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=345145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=345145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}